Navigation Links
Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract

BRAINTREE, Mass., May 29 /PRNewswire-FirstCall/ -- Haemonetics Corporation and Octapharma AG announced today the signing of a multi-year supply contract appointing Haemonetics as Octapharma's preferred provider of plasma collection technology in the United States. Under the agreement, Octapharma will use Haemonetics' technology to separate plasma from donor blood at its U.S. plasma collection centers. Plasma is the source of numerous proteins used for drug development and therapeutic purposes. These proteins include albumin, clotting factors, and intravenous immunoglobulin ("IVIG").

Octapharma, a Swiss-based company, is an independent plasma fractionation specialist, the largest privately owned plasma products company in the world. One of the top global plasma fractionators, Octapharma reported fiscal 2006 sales of euro 752 million with 37% growth year over year and has averaged revenue growth of 20% since 1995. The company owns five state of the art fractionation facilities in Austria, France, Sweden, Germany, and Mexico.

"In order to meet the increasing demand for Octapharma bio-pharmaceutical products, a key focus of the company is to extend production capacities in all our facilities. Octapharma has already started its partial vertical integration of owning plasma centers in Europe and the U.S., and it is our goal to source 50% of the plasma needed from our own centers by 2010," said Karl Erik Clausen, Chief Financial Officer of Octapharma. "Through our U.S. subsidiaries, Plasma Procurement Services, Inc. will secure Octapharma's supply of source plasma in the United States and Octapharma is pleased to be expanding its relationship with Haemonetics."

Stephen Swenson, General Manager of Global Plasma for Haemonetics, said, "Octapharma is a premier global plasma collector and fractionator, and it is the fastest growing company in the industry. We have been extremely pleased with the results relating to the European agreement we signed with Octapharma last year and are delighted to be expanding our relationship into the U.S."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at


Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
4. Octapharma Joins Biotechnology Industry Organization
5. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
8. Favrille Announces Workforce Reduction
9. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
10. Genmab Announces 2008 First Quarter Results
11. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Pittcon is pleased to announce the 2016 ... symposia, oral sessions, workshops, awards, and posters. The core of the Technical ... as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, fuels/energy, ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology:
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):